[go: up one dir, main page]

HK1005741B - Cyclosporins - Google Patents

Cyclosporins Download PDF

Info

Publication number
HK1005741B
HK1005741B HK98104804.1A HK98104804A HK1005741B HK 1005741 B HK1005741 B HK 1005741B HK 98104804 A HK98104804 A HK 98104804A HK 1005741 B HK1005741 B HK 1005741B
Authority
HK
Hong Kong
Prior art keywords
ciclosporin
meleu
hydroxy
mebmt
meval
Prior art date
Application number
HK98104804.1A
Other languages
English (en)
French (fr)
Chinese (zh)
Other versions
HK1005741A1 (en
Inventor
Young Ko Soo
Kobel Hans
Rosenwirth Brigitte
Seebach Dieter
P. Traber Rene
Wenger Roland
Bollinger Pietro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909023859A external-priority patent/GB9023859D0/en
Priority claimed from GB909023971A external-priority patent/GB9023971D0/en
Priority claimed from GB909023972A external-priority patent/GB9023972D0/en
Priority claimed from GB909023970A external-priority patent/GB9023970D0/en
Priority claimed from GB919116836A external-priority patent/GB9116836D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1005741B publication Critical patent/HK1005741B/en
Publication of HK1005741A1 publication Critical patent/HK1005741A1/en

Links

Claims (13)

  1. Verwendung eines Cyclosporins zur Herstellung eines Arzneimittels zur Behandlung und Verhütung von AIDS und mit AIDS in Beziehung stehenden Störungen, dadurch gekennzeichnet, daß das Cyciosporin
    (i) an menschliches Cyclophilin bindet mit einem Bindungsverhältnis (BR) von weniger als 0,7, wobei BR der Logarithmus zur Basis 10 des Verhältnisses der IC50 von Cyclosporin zu der IC50 von Ciclosporin, gemessen in einem kompetitiven ELISA-Test, ist und
    (ii) eine Aktivität in der gemischten Lymphoztenreaktion von nicht mehr als 5% von Ciclosporin hat.
  2. Verbindung der Formel I worin
    W MeBmt, Dihydro-MeBmt oder 8'-Hydroxy-MeBmt ist;
    X αAbu, Val, Thr, Nva oder MeOThr ist;
    R Sar oder (D)-MeAla ist;
    Y MeLeu, γ-Hydroxy-MeLeu, MeIle, MeVal, MeThr, MeAla, MeaIle oder MeaThr ist;
    Z Val, Leu, MeVal oder MeLeu ist und
    Q MeLeu, γ-Hydroxy-MeLeu oder MeAla ist;
    mit dem Vorbehalt, daß dann wenn Y MeLeu ist, daß dann entweder Z MeVal oder MeLeu ist oder W 8'-Hydroxy-MeBmt ist; zur Verwendung als Pharmazeutikum.
  3. Verbindung nach Anspruch 2 mit der Formel I' worin
    W' MeBmt oder Dihydro-MeBmt ist;
    X' αAbu oder Nva ist;
    Y' γ-Hydroxy-MeLeu, MeVal, MeThr oder MeIle ist und
    Z' Val oder MeVal ist; zur Verwendung als Pharmazeutikum.
  4. Verbindung ausgewählt aus der Gruppe umfassend:
    [Dihydro-MeBmt]1-[γ-Hydroxy-MeLeu]4-Ciclosporin
    [MeVal]4-Ciclosporin
    [MeIle]4-Ciclosporin
    [MeThr]4-Ciclosporin
    [γ-Hydroxy-MeLeu]4-Ciclosporin
    [Nva]2-[γ-Hydroxy-MeLeu]4-Ciclosporin
    [γ-Hydroxy-MeLeu]4-[γ-Hydroxy-MeLeu]6-Ciclosporin
    [MeVal]5-Ciclosporin
    [MeOThr]2-[(D)MeAla]3-[MeVal]5-Ciclosporin
    [8'-Hydroxy-MeBmt]1-Ciclosporin und
    [γ-Hydroxy-MeLeu]9-Ciclosporin
    zur Venvendung als Pharmazeutikum.
  5. Verwendung einer Verbindung nach Anspruch 2, 3 oder 4 zur Herstellung eines Arzneimittels zur Behandlung und Verhütung von AIDS und mit AIDS in Beziehung stehenden Störungen.
  6. Verbindung der Formel II worin
    W' MeBmt oder Dihydro-MeBmt ist;
    X αAbu, Val, Thr, Nva oder MeOThr ist;
    R Sar oder (D)-MeAla ist;
    Y MeLeu, γ-Hydroxy-MeLeu, MeIle, MeVal, MeThr, MeAla, MeaIle oder MeaThr ist und
    Z Val, Leu, MeVal oder MeLeu ist;
    mit dem Vorbehalt, daß dann, 1) wenn Y MeLeu oder MeAla ist, daß dann Z MeVal oder MeLeu ist und 2) wenn W' MeBmt ist, R Sar ist und Y γ-Hydroxy-MeLeu ist, daß dann Z etwas anderes als Val ist.
  7. Verbindung nach Anspruch 6 der Formel II' worin
    W' MeBmt oder Dihydro-MeBmt ist;
    Y' γ-Hydroxy-MeLeu, MeVal, MeThr oder MeIle ist und
    Z Val oder MeVal ist;
    mit dem Vorbehalt, daß dann, wenn W' MeBmt ist, Y' etwas anderes als γ-Hydroxy-MeLeu ist.
  8. Verbindung ausgewählt aus der folgenden Gruppe:
    [Dihydro-MeBmt]1-[γ-Hydroxy-MeLeu]4-Ciclosporin,
    [MeVal]4-Ciclosporin,
    [MeThr]4-Ciclosporin,
    [Nva]2-[γ-Hydroxy-MeLeu]4-Ciclosporin,
    [γ-Hydroxy-MeLeu]4-[γ-Hydroxy-MeLeu]6-Ciclosporin,
    [MeVal]5-Ciclosporin und
    [MeOThr]2-[(D)MeAla]3-[MeVal]5-Ciclosporin.
  9. [MeIle]4-Ciclosporin.
  10. Ein Verfahren zur Herstellung von [MeIle]4-Ciclosporin umfassend die Stufe, daß man den Pilzstamm DSM 6627 in einem Nährmedium züchtet und das Produkt aus der Fermentationsbrühe isoliert.
  11. Reine Kultur des Pilzstamms DSM 6627.
  12. Verfahren zur Herstellung von Cyclosporinen, die ein oder mehrere γ-Hydroxy-MeLeu-Reste haben, umfassend die Stufen, daß man den Pilzstamm DSM 6182 in einem Nährmedium züchtet, ein Cyclosporin zugibt, das ein oder mehrere MeLeu-Reste hat, und das Produkt aus der Fermentationsbrühe isoliert.
  13. Reine Kultur des Pilzstamms DSM 6182.
HK98104804A 1990-11-02 1998-06-03 Cyclosporins HK1005741A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB9023859 1990-11-02
GB909023859A GB9023859D0 (en) 1990-11-02 1990-11-02 Chemical products
GB9023972 1990-11-05
GB909023971A GB9023971D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB909023972A GB9023972D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB909023970A GB9023970D0 (en) 1990-11-05 1990-11-05 New use of a cyclosporin derivative
GB9023970 1990-11-05
GB9023971 1990-11-05
GB919116836A GB9116836D0 (en) 1991-08-05 1991-08-05 Organic compounds
GB9116836 1991-08-05

Publications (2)

Publication Number Publication Date
HK1005741B true HK1005741B (en) 1999-01-22
HK1005741A1 HK1005741A1 (en) 1999-01-22

Family

ID=27517009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104804A HK1005741A1 (en) 1990-11-02 1998-06-03 Cyclosporins

Country Status (25)

Country Link
US (3) US5767069A (de)
EP (1) EP0484281B2 (de)
JP (1) JP2740775B2 (de)
KR (1) KR100203556B1 (de)
AT (1) ATE148469T1 (de)
AU (1) AU649277B2 (de)
CA (1) CA2054590C (de)
CY (1) CY2159B1 (de)
CZ (1) CZ280909B6 (de)
DE (1) DE69124459T3 (de)
DK (1) DK0484281T4 (de)
ES (1) ES2095926T5 (de)
FI (1) FI111730B (de)
GR (2) GR3022592T3 (de)
HK (1) HK1005741A1 (de)
HU (1) HU212674B (de)
IE (1) IE913824A1 (de)
IL (1) IL99912A (de)
MX (1) MX9101869A (de)
MY (1) MY134806A (de)
NZ (1) NZ240421A (de)
PL (1) PL168609B1 (de)
PT (1) PT99410B (de)
SA (1) SA92120344B1 (de)
SK (1) SK278808B6 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014780A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas The use of a compound for the manufacture of a medicament for the treatment of hiv infection
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
ES2065273B1 (es) * 1993-05-25 1995-09-16 Biogal Gyogyszergyar Procedimiento para la purificacion de ciclosporina a.
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) * 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US6696413B2 (en) 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
NZ315324A (en) * 1995-07-17 1999-10-28 Chem Ag C Cyclosporin derivatives with anti-hiv effect
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
EP0944394A4 (de) * 1996-03-12 2003-05-14 Picower Inst Med Res Behandlung einer hiv-infektion durch beeinträchtigung der cyclophilinrezeptor-aktivität innerhalb der wirtszelle
CN1130373C (zh) * 1996-09-13 2003-12-10 诺瓦蒂斯有限公司 [3'－脱氧－3'－氧代－MeBmt]'环孢菌素制备方法
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ZA99981B (en) * 1998-02-17 2000-08-08 Du Pont Pharm Co Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors.
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
BR9911724A (pt) 1998-07-01 2001-03-20 Debiopharm Sa Ciclosporina que tem um perfil de atividade melhorado
DK1154759T3 (da) 1998-12-30 2008-12-08 Dexcel Ltd Dispergerbart koncentrat til indgift af cyclosporin
US6521595B1 (en) * 1999-11-19 2003-02-18 Lg Chemical, Ltd. Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
RU2290196C2 (ru) * 2001-04-20 2006-12-27 Дебиофарм С.А. Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение
KR100695611B1 (ko) * 2001-05-17 2007-03-14 주식회사 엘지생활건강 [감마 히드록시 엔-메틸 엘-루신4] 사이클로스포린유도체를 유효성분으로 하는 모발 성장 촉진제
KR100978836B1 (ko) * 2001-10-19 2010-08-30 이소테크니카 인코포레이티드 신규한 시클로스포린 유사체 미세유화액 예비농축물
SI1436321T1 (sl) 2001-10-19 2006-12-31 Isotechnika Inc Sinteza analogov ciklosporina
DE20220744U1 (de) * 2001-10-25 2004-05-13 Viromics Gmbh Mittel zur Hemmung von Lentiviren
US7108988B2 (en) * 2001-11-02 2006-09-19 The J. David Gladstone Institutes Methods of identifying agents for inhibiting lentivirus replication
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
KR20070036127A (ko) * 2004-07-13 2007-04-02 노파르티스 아게 알츠하이머병을 치료하기 위한 사이클로스포린
DE602005026294D1 (de) 2004-07-14 2011-03-24 Novartis Ag Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
KR100597309B1 (ko) 2004-09-17 2006-07-05 주식회사 핸슨바이오텍 세베키아 베니하나를 이용한 [감마 히드록실메틸루신4] 사이클로스포린 a의 제조방법
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
EP1804823A4 (de) 2004-09-29 2010-06-09 Amr Technology Inc Neue cyclosporin-analoga und ihre pharmazeutischen anwendungen
KR101309409B1 (ko) * 2004-10-01 2013-09-23 싸이넥시스, 인크. Ｃ형 간염 바이러스 감염의 치료 및 예방을 위한 ３-에테르및 ３-티오에테르 치환된 시클로스포린 유도체
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7361636B2 (en) * 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
KR100777488B1 (ko) 2004-12-15 2007-11-28 주식회사 핸슨바이오텍 세베키아 베니하나 (Sebekia benihana)배양물로부터 감마-히드록실메틸루신4 사이클로스포린 A를 효과적이고 선택적으로 회수하는 방법
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
WO2006071618A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compounds for flaviviridae treatment
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2007133865A2 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
EP2027761A1 (de) * 2006-06-02 2009-02-25 Claude Annie Perrichon Verwaltung von aktieven elektronen
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
AU2008304313B2 (en) * 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
AU2009276241A1 (en) 2008-07-30 2010-02-04 Ciclofilin Pharmaceuticals Corp. Nonimmunosuppressive cyclosporine analogue molecules
CA2748389A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
GB0909754D0 (en) * 2009-06-05 2009-07-22 Magnani Mauro Drug delivery systems
CN102811998B (zh) * 2009-12-21 2016-03-30 国家健康与医学研究院（Inserm） 新的亲环素抑制剂及其用途
US20120010131A1 (en) 2009-12-30 2012-01-12 Scynexis, Inc. Novel cyclosporin analogues
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
MY192981A (en) 2010-12-15 2022-09-20 Contravir Pharmaceuticals Inc Cyclosporine analogue molecules modified at amino acid 1 and 3
US20120253007A1 (en) * 2011-03-28 2012-10-04 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Synthesis of Cyclosporin H
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296A4 (de) 2018-07-20 2022-04-27 Lipocine Inc. Lebererkrankung
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
AU2020363688A1 (en) 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
WO2021190601A1 (en) 2020-03-26 2021-09-30 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof
CA3174545A1 (en) 2020-04-15 2021-10-21 Ching-Pong Mak Prevention and treatment of organ injuries

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2463138C2 (de) 1973-12-06 1984-07-05 Sandoz-Patent-GmbH, 7850 Lörrach Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung
US4304855A (en) * 1977-05-05 1981-12-08 The Upjohn Company Allylic methyl-hydroxylated novobiocins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP0194972B1 (de) * 1985-03-11 1992-07-29 Sandoz Ag Cyclosporine
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
EP0283801A3 (de) * 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
EP0373260B1 (de) * 1987-06-22 1994-03-09 Merck & Co. Inc. Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4914188A (en) † 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5081024A (en) * 1988-09-05 1992-01-14 Nissan Chemical Industries, Ltd. Process for producing optically active amino acids
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8

Similar Documents

Publication Publication Date Title
EP0484281B1 (de) Zyklosporine
HK1005741B (en) Cyclosporins
EP0056782B1 (de) Cyclosporine
US4914188A (en) Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
JP4350898B2 (ja) 活性の特徴が改善された新規のシクロスポリン
CA1247546A (en) Cyclosporins
US5116816A (en) Cyclosporin peptolides having an α-hydroxycarboxylic acid at position 8
US6979671B2 (en) Cyclosporins for the treatment of immune disorders
US20030104992A1 (en) Cyclosporin analogs for the treatment of autoimmune diseases
US20040266669A1 (en) Cyclosporin derivatives for the treatment of immune disorders
GB2207678A (en) Novel immunosuppressive fluorinated cyclosporin analogs
RU2085589C1 (ru) Циклоспорины
AU596071B2 (en) Novel cyclosporins
NO310028B1 (no) Cyklosporiner, deres anvendelse og fremstilling samt en biologisk ren kilde
RO110144B1 (ro) Noi ciclosporine, procedeu de sinteză a acestora și metodă de tratament și prevenire a SIDA